Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Acquisitions (2018)

Harvard Bioscience (HBIO) has disclosed Acquisitions for 6 consecutive years, with $540000.0 as the latest value for Q4 2018.

  • On a quarterly basis, Acquisitions changed N/A to $540000.0 in Q4 2018 year-over-year; TTM through Sep 2019 was $540000.0, a 99.21% decrease, with the full-year FY2018 number at $68.5 million, changed N/A from a year prior.
  • Acquisitions was $540000.0 for Q4 2018 at Harvard Bioscience, down from $595000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $67.4 million in Q1 2018 to a low of $540000.0 in Q4 2018.
  • A 3-year average of $17.1 million and a median of $4.5 million in 2015 define the central range for Acquisitions.